Check-in and registration
The field of market shaping is at a critical juncture. The last ten years have seen huge global health impacts and success from market shaping interventions. However, significant challenges exist that risk continued progress and success. This Global Health Market Shaping conference aims to provide a forum for the market shaping community to examine priority issues and build foundations for future collaboration to address them.
Christopher Lim (Chief, Strategic Funds, WHO-PAHO); David Ripin (Executive Vice President of Infectious Diseases & Chief Science Officer, CHAI); Padmashree Gehl Sampath (CEO, African Pharmaceutical Technology Foundation; Senior Advisor to the President, African Development Bank); Rajnikant Vora (Chairman, Revital Healthcare); Greg Widmyer (Senior Advisor, Bill & Melinda Gates Foundation)
Global health markets archetypes and demand contexts vary widely based on many factors including programmatic goals, level of consolidation, regulatory and policy pathway clarity, donor involvement, and size and volatility. It is critical to define types of demand from the outset and the goal of market shaping on the demand side. How can we categorize and understand the different demand contexts in which we work? What are the common objectives we aim for with demand-side market shaping efforts?
Marie Chantale Lepine (Acting Vice President, Global Markets, CHAI); Mila Nepomnyashchiy (Deputy Director, Center for Innovation and Impact, USAID)
There is a struggle to achieve healthy, sustainable markets in particularly challenging market contexts, such as low-volume or volatile, unpredictable markets, to name only a few. Across different contexts, what level of demand predictability, materialization, and reliability is achievable? What lessons learned or best practices can we summarize for effective market shaping in more complex market situations?
The discussion will be split into two tracks:
TRACK A: Shaping small and fragile markets
TRACK B: Markets transitioning out of donor-funded procurement
Ensuring alignment between demand and supply lies at the heart of market-shaping efforts and involves multiple stakeholders coordinating efforts across the entire value chain. How can we better align supply and demand? Which incentives and strategies are most effective? How can we ensure supply meets country-level and end-user preferences?
Janet Ginnard (Director, Strategy, Unitaid); Khatuna Giorgadze (Partner, Linksbridge); Kristina Lorenson (Senior Contract Manager, UNICEF); Ellie Marsh (Senior Manager, Strategy, Procedure and Innovation, Supply Operations, The Global Fund); David McGuire (Director, Access and Market Shaping, IVCC); Harsh Mehta (Director of International Business Development, Revital Healthcare); Kenly Sikwese (Executive Director, AfroCAB Treatment Access Partnership)
Given the evident importance of demand-side factors to healthy markets and successful market shaping, it is critically important to ensure market shaping activities are supportive of and responsive to national-level ownership, priorities, and decision-making. Recent initiatives showcase novel approaches to engage global-, regional- and national-level actors together to understand market issues and set market shaping priorities. What can be learned, improved, and applied elsewhere using these examples?
Olawale Ajose (Managing Partner, Market Access Africa); Abyu Farris (Associate Director, Results for Development); Pape Amadou Gaye (Founder & President, Baobab Institute for Health and Development); Nelsha Haji (Associate Director, Market Shaping Practice, Results for Development); Machumu Stephen Miyeye (Reproductive, Maternal and Child Health Commodity Security Coordinator, Tanzania MoH)
Global health markets are complex and dynamic, and market interventions have potential to do harm. In the market shaping ecosystem, actors are all dependent on one another’s actions for their own success. This kind of system requires consistent and high levels of efficient coordination, collaboration, and capability from all partners to get the best results. At a community level, where do we need to improve and how can we achieve this? What tools do we have or do we need to continue improving into the future?
Gaurvika Nayyar (Senior Program Officer, Vaccine Access, Bill & Melinda Gates Foundation); Dena Seabrook (Director, Linksbridge)
Effective and efficient coordination with appropriate partners is critical to the success of any market shaping intervention. With more actors engaged in market shaping than ever before, this becomes increasingly challenging. What are the best approaches and processes to working together to inform, design, and implement market shaping interventions and commercial agreements? What common risks or pitfalls should actors be aware of? What tools and resources can help achieve this and where should we work to improve as a community?
TRACK A: Fundamentals for success: what sets up interventions to add required value and avoid unintended consequences?
TRACK B: Ensuring sustainable mutual value: what determines whether interventions can survive market conditions and achieve impact?
TRACK C: Effective collaboration: how should global health entities manage interventions from inception through the remainder of their lifecycles?
TRACK D: Impact achievement: what is required for meeting target outcomes and monitoring and evaluating success?
TRACK E: Transparency with partners: how can global health actors use mutual review to scrutinize ideas, align on needed market interventions, and collectively learn from their experiences?
From navigating efforts to scale up local manufacturing capacity to addressing climate change to preparing for the next pandemic, there are numerous market challenges and shifts to navigate in the coming decade. How are industry partners strategizing, prioritizing, and preparing to tackle what is ahead?
James Anderson (Executive Director, Global Health, IFPMA); Claudia Martinez (Head of Research, Access to Medicine Foundation); Harsh Mehta (Director of International Business Development, Revital Healthcare); Belinda Ngongo (Director, Global Health, Illumina); Aayush Solanki (Global Development Advisor, bioLytical Laboratories)
Along the supply chain, many market obstacles and bottlenecks arose in our efforts to supply Covid-19 health products during the pandemic. What knowledge can we take away about healthy market strategies, interventions, and approaches for pandemic or volatile market situations? How would we approach this situation differently in the future in light of these lessons learned, new technology, and innovative approaches? What are the ongoing pandemic preparedness initiatives and the dual-purpose investment opportunities?
Tara Herrick (Director of Market Analytics and Insights, PATH); Dominic Hein (Director, Market Shaping, Gavi); Derrick Sim (Managing Director, Vaccine Markets and Health Security, Gavi); Tara Prasad (Team Lead, Global Access, WHO); Alice Sabino (Strategic Public Partnership Lead, CEPI)
The huge diversity of organizations within the private sector supply system (e.g., manufacturers, distributors, and other delivery partners) is not well-understood across the market shaping ecosystem. Reviewing the variety of private sector suppliers and their different operating models, what are the incentives, limitations, and opportunities for better engagement in global health market shaping?
Allan Eyapu (Market Dynamics Advisor, Population Services International); Judith Kallenberg (Lead, Global Health Access Programs and Partnerships, GlaxoSmithKline); Seth McGovern (Head, Market Dynamics and Analytics, Population Services International); Harsh Mehta (Director of International Business Development, Revital Healthcare); Aayush Solanki (Global Development and Strategy Lead, bioLytical Laboratories)
Trends toward local production and regional manufacturing present a paradigm shift for global health markets. What implications, challenges, and opportunities does this pose?
Hassan Belkhayat (Co-founder, Southbridge A&I); Nafisa Jiwani (Associate Vice President, Health Initiatives, Office of Health and Agriculture, U.S. International Development Finance Corporation); Yalda Momeni (Senior Specialist, Future Supplier Base Strategy, Gavi); Mohamed Ndiaye (Senior Advisor for Strategy, Planning & Financing, Director of the Delivery Unit, Institut Pasteur Dakar); Greg Widmyer (Senior Advisor, Bill & Melinda Gates Foundation); Prashant Yadav (Affiliate Professor, INSEAD; Lecturer, Harvard Medical School)
The global health market shaping community has historically focused on managing centralized markets characterized by a few big buyers, a limited number of suppliers, and a relatively clear delivery path. However, these centralized markets are fragmenting, with increasing numbers of public and private buyers, growing numbers of suppliers and product choices, expanding service delivery channels, and consumers increasingly managing their own healthcare decisions. Thus, we need to spend more time learning from partners who have been influencing adoption, supply, prices, and quality in these more complex environments. What are their challenges and how might we tackle them? Where can we apply some of their successful strategies more broadly? What issues make sense to tackle independently versus together?
Joanna Bichsel (Founder and CEO, Kasha Global); Blair Hanewall (Independent Consultant and former Executive Director, SEMA Reproductive Health); Lisa Smith (Global Program Leader, Market Dynamics, PATH); Ioana Ursu (Senior Manager, Global Insight and Access, IVCC)
Private sector market data is weak despite the acknowledgment that many people in low- and middle-income countries access care through the private sector. How can we better understand and engage with private sector markets?
Swarnika Ahuja (Manager, Market Innovations Unit, FIND); Nelsha Haji (Associate Director, Market Shaping, Results for Development); Seth McGovern (Head, Market Dynamics and Analytics, Population Services International); Pam Pillay (Principal, Diagnostics and Laboratories, Market Access Africa)
New manufacturing technologies have potential to change the game for health product delivery. What are possible applications for these new technologies? How can they help address existing or potential market failures?
Connie Cai (Senior Strategy Officer, Bill & Melinda Gates Foundation); Olivier Defawe (Director, Private Sector Engagement, VillageReach); Khatuna Giorgadze (Partner, Linksbridge); Belinda Ngongo (Director, Global Health, Illumina)
An off-site dinner will be hosted at Cuines Santa Caterina (Avinguda de Francesc Cambó, 16, 08003) located inside Barcelona’s Santa Caterina Market. The restaurant is a ten-minute walk from the conference venue.
Market shaping finance tools—such as volume and procurement guarantees and product development incentives—are among the most-used market shaping interventions of the last decade. The structure and approaches to using them have evolved significantly. Focusing on a set of key instruments, how have they evolved along a range of dimensions, such as diversity of markets addressed and suppliers engaged, contract and partnership structure, negotiations, and implementation approaches? How can we maximize the impact of market shaping finance tools going forward?
Ellie Marsh (Senior Manager, Strategy, Procedure and Innovation, Supply Operations, The Global Fund); Ademola Osigbesan (Technical Manager, Strategic Sourcing and Supply, Unitaid); Hema Srinivasan (Chief Access Officer, MedAccess); Alan Staple (Vice President, Global Markets, CHAI)
Impact investing and market shaping organizations frequently operate in the same markets or focus areas. While the activities of both fields can have notable similarities, the fundamental goals, incentives, and approaches differ in important ways. How should market shaping actors engage with impact investing actors going forward?
Michael Anderson (CEO, MedAccess); Raffaele Cordiner (Senior Investment Officer, EIB Global); Nafisa Jiwani (Associate Vice President, Health Initiatives, Office of Health and Agriculture, U.S. International Development Finance Corporation)
Funding priorities and strategies for market shaping set the direction and evolution of the field. What are current donor priorities, and how are they changing? How do funding agencies coordinate their efforts? What keeps people up at night, and what are they most excited about when it comes to the future of market shaping?
Claudia Harner-Jay (Senior Advisor, Market Dynamics, PATH); Janet Ginnard (Director, Strategy, Unitaid); Mila Nepomnyashchiy (Deputy Director, Center for Innovation and Impact, USAID); Greg Widmyer (Senior Advisor, Bill & Melinda Gates Foundation)
Closing discussion on lessons learned, key takeaways, and priorities for action identified throughout the conference.
Gaurvika Nayyar (Senior Program Officer, Vaccine Access, Bill & Melinda Gates Foundation)
Global Health Market Shaping Conference
GHMS 2024